Special Issue

Inoviruses

Message from the Guest Editors

Inoviruses are filamentous bacteriophages that cause a chronic infection of their bacterial host. Significant research has been conducted into the classic inovirus M13 for its molecular biology and biotechnology applications. However, there is limited research into the impact of inoviruses on the fitness and virulence of multidrug-resistant bacterial pathogens. In this Special Issue, we aim to gather contributions that advance the current knowledge on the role and impact of these unique understudied phages on bacterial fitness, microbial pathogenesis, and host–pathogen interactions. Manuscripts of original research, reviews, mini-reviews, commentary and perspectives on the following areas of inovirus study are particularly welcome:

- Identification of novel inoviruses, including the use of viral metagenomics approach
- Contribution to bacterial pathogenesis
- Inoviruses as virulence factors
- Prevalence in multidrug-resistant pathogens
- Targets for vaccine development (pre-clinical studies)
- Impact on bacterial fitness
- Other inoviruses research areas

Guest Editors

Dr. Danielle Peters

Human Health and Therapeutics Research Center (HHT), National Research Council Canada, Ottawa, ON, Canada

Prof. Dr. Wangxue Chen

Human Health and Therapeutics Research Center (HHT), National Research Council Canada, Ottawa, ON, Canada

Deadline for manuscript submissions

closed (24 December 2024)



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/164242

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34

mdpi.com/journal/ viruses

viruses@mdpi.com





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAq, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).